The TCT 2024 Career Achievement Award will be presented to Robert A. Harrington, MD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 27-30 2024, in Washington, DC at the Walter E. Washington Convention Center.
The American Association for Thoracic Surgery (AATS) and the Cardiovascular Research Foundation (CRF) announced today a strategic partnership for CRF’s New York Valves 2024: The Structural Heart Summit, making AATS the exclusive cardiothoracic surgical society partner of this preeminent valve meeting.
The Cardiovascular Research Foundation (CRF) is excited to introduce New York Valves: The Structural Heart Summit, the expanded next iteration of our renowned annual Transcatheter Valve Therapy (TVT) conference.
Media registration is now open for TCT 2024 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF).
The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An international heart failure conference organized by the Cardiovascular Research Foundation® (CRF®), THT will take place March 4-6, 2024, at the Westin Boston Seaport in Boston, MA.
The Cardiovascular Research Foundation (CRF), in conjunction with the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference, CRF's annual scientific symposium, announced today the launch of the CRF Scientific Excellence Top 10 (SET-10), a new global annual ranking recognizing academic contributions to interventional cardiovascular medicine.
– The Cardiovascular Research Foundation (CRF) is pleased to announce that HeartPoint Global has won the TCT 2023 Shark Tank Innovation Competition for its novel multi-lumen stent system for interventional adjustment of pulmonary blood flow in congenital heart disease. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine, October 23-26 in San Francisco. The winner was also presented with the Jon DeHaan Foundation Award for Innovation in Cardiology.
Walgreens and the Cardiovascular Research Foundation (CRF) today announced a collaboration to drive forward the PREVUE-VALVE study, a groundbreaking population-based clinical trial that aims to quantify the prevalence of valvular heart disease (VHD) among older Americans and pave the way for the development of new therapies and tools for VHD detection and diagnosis.
The Cardiovascular Research Foundation (CRF) is proud to announce the winners of the 2023 Pulse-Setter Awards. The awardees will be honored at The Annual Pulse of the City Gala, CRF’s signature fundraising event, on December 8, 2023, at The Plaza in New York City. The Pulse-Setter Awards shine a spotlight on extraordinary individuals and initiatives whose dedication to innovation is driving positive change in medicine and health care.
The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical trials. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine.
Building on the resounding success of last year’s standing-room-only debut, the Cardiovascular Research Foundation (CRF) and Fogarty Innovation are proud to present an even more dynamic and comprehensive TCT MedTech Innovation Forum in 2023. The highly anticipated program will feature additional learning tracks, expanded networking opportunities, increased attendee capacity, and the TCT Shark Tank Innovation Competition. The day-long interactive summit will take place on the first day of TCT 2023 (Transcatheter Cardiovascular Therapeutics), CRF’s esteemed annual scientific symposium, October 23–26, at The Moscone Center in San Francisco, California.
The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 Program Guide is now available. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. TCT 2023 will take place October 23-26 in San Francisco, California, at the Moscone Center and will celebrate 35 years of leading the field.
The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 15 Late-Breaking Clinical Science studies. An annual meeting featuring cutting-edge research and techniques for structural heart interventions, TVT will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona.
The program guide for TVT 2023: The Structural Heart Summit is available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 7-10, 2023, at the Phoenix Convention Center – West in Phoenix, Arizona.
The TCT 2023 Career Achievement Award will be presented to Stuart J. Pocock, PhD, during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 23-26, 2023, in San Francisco at the Moscone Center. The award is given each year to an outstanding individual who has made significant contributions to the field of interventional cardiology and transformed patient care through their career endeavors, research pursuits, and mentorship.
Media registration is now open for TCT 2023 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. TCT, which will be held October 23-26, 2023 in San Francisco, California at the Moscone Center, will be celebrating 35 years of leading the field.
The full list of late-breaking clinical science to be presented at THT 2023: Technology and Heart Failure Therapeutics is now available online. An international heart failure conference organized by the Cardiovascular Research Foundation (CRF), THT will take place March 20-22, 2023, at the Westin Boston Seaport in Boston, MA.
The TCT Geoffrey O. Hartzler Master Operator Award will be presented to William L. Lombardi, MD during Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will take place October 23-26, 2023, in San Francisco at the Moscone Center. The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and leadership.
CTO Plus 2023 will feature the latest research and techniques for chronic total occlusions (CTO) and complex percutaneous coronary interventions (PCI). The annual conference, organized by the Cardiovascular Research Foundation (CRF), will take place February 23-24 at the New York Marriott Marquis in New York, NY.
The Cardiovascular Research Foundation (CRF) announced today that Alexandra Popma, MD, has joined the organization as Executive Director of the CRF Clinical Trials Center.
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine, September 16-19 in Boston. The winner was also presented with the Jon DeHaan Foundation Award for Innovation in Cardiology.
Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL transcatheter valve repair system was non-inferior compared with MitraClip in patients with significant symptomatic DMR who are not eligible for mitral valve surgery. Findings from the CLASP IID trial were reported today at TCT 2022, the 34th annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
An analysis from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry found that most patients with severe mitral regurgitation (MR) and cardiogenic shock (CS) who underwent mitral transcatheter edge-to-edge repair (TEER) in the United States achieved successful MR reduction, and that successful repair was associated with lower mortality and heart failure (HF) hospitalizations at one year post-procedure compared with unsuccessful repair.
The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program is now available for the TCT MedTech Innovation Forum. The summit will be held on the first day of TCT, the annual scientific symposium of CRF, on Friday, September 16. TCT will take place September 16-19, 2022, in Boston, Massachusetts, at the Boston Convention and Exhibition Center.
Two leaders in cardiovascular disease science, research and education, the American Heart Association (Association) and the Cardiovascular Research Foundation (CRF), are joining forces to strengthen and expand educational opportunities focused on advancing the latest research in cardiovascular disease and interventional therapies. The new alliance to produce joint education programs begins immediately with the organizations’ annual scientific meetings this fall. The Association will present educational programming from its annual Scientific Sessions at TCT, and CRF will deliver educational programming from its annual scientific symposium Transcatheter Cardiovascular Therapeutics (TCT) at the Association’s Scientific Sessions, beginning with TCT 2022, September 16-19 in Boston, and the Association’s Scientific Sessions 2022, November 5-7 in Chicago, respectively.
The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical science that will be presented at TCT 2022. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place September 16-19 in Boston, Massachusetts at the Boston Convention and Exhibition Center.
The TCT Career Achievement Award will be presented to Valentin Fuster, MD, PhD, on September 17, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). The award is given each year to an outstanding individual who has made significant contributions to the field of interventional cardiology and transformed patient care through their career endeavors, research pursuits, and mentorship of others.
The TCT Geoffrey O. Hartzler Master Operator Award will be presented to Jean Fajadet, MD, on September 18, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and innovation.
The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that they are joining forces to launch the "TCT MedTech Innovation Forum” just before the main sessions of TCT (Transcatheter Cardiovascular Therapeutics) 2022, the annual scientific symposium of CRF. TCT will be held September 16-19, 2022, in Boston, Massachusetts at the Boston Convention and Exhibition Center.
The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. An annual meeting covering cutting-edge research and techniques for structural heart interventions, TVT will take place June 8-10, 2022, at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
The program for TVT 2022: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 8-10, 2022 at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
Media registration is now open for TCT 2022 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will be held September 16-19, 2022, in Boston, Massachusetts at the Boston Convention and Exhibition Center.
CTO Plus 2022 will feature the latest research and techniques for chronic total occlusions (CTO) as well as complex percutaneous coronary interventions (PCI). The annual conference, organized by the Cardiovascular Research Foundation (CRF), will take place February 24-25, 2022 at the New York Marriott Marquis in New York, NY. Online access to the live cases and discussions will be complimentary. The full program is now available online.
The program for THT 2022: Technology and Heart Failure Therapeutics is now available online. THT is the first-ever conference on technology and heart failure therapeutics from the Cardiovascular Research Foundation (CRF). The meeting, which explores new and emerging treatments and innovative monitoring strategies, will take place February 1-2, 2022 online and in person, at the New York Marriott Marquis in New York, NY.
The Cardiovascular Research Foundation (CRF) is pleased to announce that Lungpacer Medical, a clinical stage medical device company pioneering a diaphragm pacing therapy system for critically ill patients who require mechanical ventilation, has won the TCT 2021 Shark Tank Innovation Competition, which took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine. The winner was also presented with the Jon DeHaan Foundation Award for Interventional Innovation.
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA). The study showed that the two devices achieve a similar rate of LAA occlusion at 45 days but through different mechanism. Furthermore, Amulet as compared with Watchman FLX was associated with higher procedural complications but similar clinical outcomes at 45-days.
Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE trial found that nearly all patients receiving antiplatelet therapy developed evidence of abnormal gastrointestinal (GI) mucosal findings on capsule endoscopy. Dual antiplatelet therapy (DAPT) followed by single anti-platelet therapy (SAPT) led to less GI injury than continued DAPT.
Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis but a higher rate of access-site or access-related vascular complications.
An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at 2-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at 2-years, TAVR was cost-effective for these patients.
Results from SUGAR, a randomized, controlled, multicenter trial conducted exclusively in patients with diabetes mellitus (DM) and with minimum exclusion criteria, found that amphilimus-eluting stents (AES) were superior to zotarolimus-eluting stents (ZES) with regard to target lesion and target vessel failure composite outcomes at one year.
The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 trial found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for one-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease. Patients with a low SYNTAX score (which measures the complexity of coronary artery disease) had less incidence of adverse events compared to those with intermediate or high SYNTAX scores, and in this cohort of patients PCI performed more favorably.
Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further blood pressure reductions after RDN with a smaller increase in additional medications prescribed and less use of diuretics.
The FAVOR III China trial found that lesion selection for percutaneous coronary intervention (PCI) using the non-invasively assessed physiologic measurement quantitative flow ratio (QFR) improved outcomes for PCI compared with a standard angiography-guided strategy.
New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery. Although there were initially more reinterventions after TAVR, the rates were similar after two years and key clinical endpoints were also similar.
The Cardiovascular Research Foundation (CRF) is pleased to announce that the digital component of TCT 2021 will now be free for the entire interventional community. After careful consideration and achieving a critical level of support, CRF’s leadership has agreed to fully support this initiative. Complimentary online registration will include access to all content via livestream during the meeting and on-demand access for one year.
The Cardiovascular Research Foundation (CRF) will stream select abstracts from Transcatheter Cardiovascular Therapeutics (TCT) 2021 throughout the month of October. These free sessions will be streamed on Twitter and Facebook.
The Cardiovascular Research Foundation (CRF) has announced 22 late-breaking trial and science presentations that will be reported at TCT 2021. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place November 4-6, 2021 in Orlando, Florida at the Orange County Convention Center and simultaneously broadcast live.
Media registration is now open for TCT 2021 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will be held November 4-6, 2021 in Orlando, Florida at the Orange County Convention Center and simultaneously broadcast live.
The Cardiovascular Research Foundation (CRF) announced that TVT 2021 will feature 12 studies as Late-Breaking Clinical Science. An annual meeting from CRF, TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.
The program for TVT 2021: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right